Protocol Number: KS301P107
Principal Investigator: Nathan Pezda, M.D.
The purpose of this study is to determine whether study treatment with KSI-301 is safe and effective in the treatment of wAMD (wet age-related macular degeneration), compared with the standard treatment with aflibercept (also called Eylea®). The standard treatment for wAMD is eye injections every month or every other month to decrease the swelling of the light-sensitive tissue at the back of the eye (retina). These injections work by blocking a protein in the eye called vascular endothelial growth factor (VEGF). When there is too much VEGF inside the eye because of wAMD, swelling can occur, which results in vision loss. KSI-301 is designed to decrease fluid leakage and swelling in the retina by blocking VEGF. KSI-301 is an investigational drug, which means it is a drug that is being tested and has not yet been approved by regulatory authorities, such as the US Food and Drug Administration (FDA). However, the regulatory authorities have been provided with the necessary information to allow studies of KSI-301 in people.